Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and Evgen Pharma to explore treatment for osteoarthritis
Researchers will investigate the potential of the drug SFX-01 as a treatment for osteoarthritis.
Work will build on a previous collaboration

The RVC and Evgen pharma have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) for a four-year PhD studentship focused on investigating treatment for osteoarthritis.

The Industrial Co-operative Awards in Science & Technology (CASE) PhD Studentship will allow researchers to investigate the potential of the drug SFX-01 as a treatment for the disease, which affects almost 9 million people across the UK.

The work will build on a previous collaboration, which showed that mice with spontaneously-arising osteoarthritis demonstrated significantly improved bone architecture and preservation of normal movement following three months of SFX-01 treatment.

Professor Andrew Pitsillides, who led the study, said: “Myself and my colleagues Drs Isabel Orriss and Behzad Javaheri in the RVC’s Skeletal Biology Group are very excited by the prospect of working with Evgen Pharma to identify the cellular and molecular targets by which SFX-01 exerts its beneficial actions in osteoarthritis.”

Evgen Pharma is a clinical stage drug development company that focuses on the treatment of cancer and neurological conditions.

CEO Dr Stephen Franklin commented: “As a Company, we remain focused on the delivery of our current Company sponsored clinical trials and our strategic focus is in cancer and neurology. 

“We will, however, provide SFX-01 to a limited number of world leading academics and clinical groups that wish to investigate SFX-01 in alternative therapeutic areas if they can demonstrate a robust clinical plan, source their own non-dilutive grant funding and we retain commercialisation rights.

“We, and the RVC, are delighted that the BBSRC is funding this programme and it is another step towards the possibility of a future, grant funded, clinical trial on SFX-01 in osteoarthritis”. 

Become a member or log in to add this story to your CPD history

Free bloat webinar planned for dog owners

News Story 1
 The Kennel Club is inviting dog owners to attend a free webinar on gastric dilation-volvulus syndrome, also known as bloat.

Part of its health webinar series, the session will take place from 7pm to 8pm on 12 November. It will explore what scientific research has revealed about causes, symptoms, breed susceptibilities, diagnostic approaches, and treatment options, as well as looking at what future research could uncover.

The talk will be hosted by Mark Dunning, professor of small animal internal medicine at the University of Nottingham, and will include a 30-minute Q&A session.

Places can be booked here

Click here for more...
News Shorts
FIVP to represent independent practices at London Vet Show

The Federation of Independent Veterinary Practices (FIVP) will be at stand (S05) at this year's London Vet Show.

The not-for-profit organisation will be explaining how its expertise and resources can help independent practices to thrive in a competitive industry. It will also share how it has been representing independent practices in the ongoing CMA investigation.

On Thursday, FIVP member Steve Carter will be available to discuss how veterinary surgeons and nurses can pursue practice ownership.

FIVP will also be offering independent practices three months of free membership if they sign up at the stand.

Rita Dingwall, FIVP business development manager, said: "It's a wonderful opportunity to discuss our representation in the CMA enquiry and connect with like-minded individuals who share our passion for independent practice."